Notes: This paper discusses the inhibition of PCR by reverse transcriptases. The inhibitory effect was overcome by increasing template concentration to more than 10^5 to 10^6 copies or including T4 gene 32 protein during the reverse transcription phase of the reaction. The poly(A)+ RNA used in the study was isolated using the PolyATtract® mRNA Isolation System. (1357)

Notes: Chromosomal E.coli DNA was prepared with the Wizard^® Genomic DNA Purification Kit and used for PCR. The resulting PCR fragments were purified with the Wizard^® PCR Preps DNA Purification System and used for fluorescent sequencing. (0203)

Notes: Genomic analysis noted a single base change between wild type and mutant. To see if this base change was enough for alternative mRNA splicing, minigenes were constructed and subcloned into the pTargeT™ Vector. The mutant and wild-type minigenes were transfected into COS-1 cells. Forty-eight hours post-transfection total RNA was isolated and analyzed by RT-PCR. Transfectants with the mutant sequence did produce a different product due to alternative splicing. (1331)

Notes: Poly A+ RNA was isolated directly from PBS-perfused mouse lungs with the PolyATtract^® System 1000. The isolate poly A+ RNA was used for quantitative two-step RT-PCR using M-MLV RNase Hminus Reverse Transcriptase as well as RNasin^® Ribonuclease inhibitor for first step cDNA synthesis. (0821)

Notes: cDNA was generated by reverse transcription of RNA purified from lymphoblastoid cell lines. PCR amplification of the cDNA was used to introduce a 17bp consensus T7 promoter sequence and a mammalian translation-initiation sequence in frame with a unique hMLH1 or hMSH2 sequence. Resultant PCR products were translated in the TNT^® T7 Coupled Reticulocyte Lysate System. (1194)

Notes: ()

Notes: The Wizard^® Genomic DNA Purification Kit was used to isolate genomic DNA from transgenic mouse peripheral blood lymphocytes. The isolated genomic DNA was used for PCR analysis of the CD95 genotype. (0718)

Notes: The Access RT-PCR System was used for a semi-quantitative assessment of the quantity of Cu/Zn superoxide dismutase (Cu/Zn SOD) Mn superoxide dismutase (Mn SOD) mRNA levels. Primary embryonic hippocampal neurons were treated with Abeta(25-35) for zero to 25 hours. The level of the Cu/Zn SOD and Mn SOD mRNA was related as percent of control, untreated cultures. The PCR portion of the reaction was performed for 22 cycles to insure that the reaction was in the linear range. (0106)

Notes: PCR products were excised, eluted, and precipitated prior to sequencing with the fmol^® DNA Cycle Sequencing System. Promega's RNasin^® Ribonuclease Inhibitor and AMV Reverse Transcriptase were used in a reverse transcription assay. (2065)

Notes: The system was used to isolate total RNA from Jurkat cells. The isolated RNA was used for RT-PCR. The RT reaction was catalyzed by MMLV Reverse Transcriptase. (1662)

Notes: The authors used T4 RNA Ligase to circularize highly purified total mitochondrial tRNA prior to RT-PCR. (1083)

Notes: The pGEM®-5Zf(+) Vector was used for subcloning of a PCR fragment. The fragment was used to make a probe for RNase protection assays. The pGEM®-7Zf(+) Vector was used for routine subcloning of restriction fragments from the chitotriosidase gene. (1427)

Notes: The Access RT-PCR System was used to assess expression of the CIITA gene in fibroblast L and splenic B cells. The 700bp transcript could be detected with as little as 40ng of poly(A)+ RNA from the splenic B cells but undetectable in as much as 5µg of poly (A)+ RNA from the L cells. Both sources of RNA were readily amplified for a 510bp β-actin message from 5µg down to 40ng. (0657)

Notes: PCR products were purified by Wizard^® PCR Preps DNA Purification System and sequenced with the fmol^® DNA Cycle Sequencing System. (0576)

Notes: The Serine/Threonine Phosphatase Assay System was used to assess protein phosphatase 2A, 2B and 2C activity in nuclear extracts of Human umbilical vein cells (HUVEC) with or without lysophosphatidylcholine treatment. Gel shifts were also performed with nuclear extracts prepared from the HUVEC cells using the SP1 Consensus Oligonucleotide. Luciferase reporter studies were also performed in HUVEC cells using pGL3 Basic-derived vectors and the Luciferase Assay System. (1305)

Notes: The Tfx™-50 Reagent was used to stably transfect 293 cells. Successful stable transfection was judged by RT-PCR and functional assays. (1079)

Notes: Plasmid DNA was purified with the Wizard® Plus Miniprep DNA Purification System and further purified for microinjection. Transgenic zebrafish were identified by PCR using Taq DNA Polymerase. PCR products were resolved on gels with the 100bp DNA Ladder as a size marker. (1183)

Notes: The Access RT-PCR System was used to study expression of Bcl-2, A1, Bax and Bad genes in HUVE (human umbilical vein endothelial) cells treated with VEGF (vascular endothelial growth factor). The technique of 'real-time' quantitative RT-PCR was employed. (1150)

Notes: The CellTiter 96^® AQ_ueous Non-Radioactive Cell Proliferation Assay was used to monitor the proliferative response of human umbilical vein endothelial cells to VEGF-C. RT-PCR was performed in the presence of RNasin^® Ribonuclease Inhibitor. (0146)

Notes: The RNAgents^® Total RNA Isolation System was used to isolate total RNA from the livers of normal and factor IX-knockout mice. The RNA was used for RT-PCR. (0765)

Notes: The Riboprobe^® in vitro Transcription System was used to produce ³²P-labeled RNA probes for RNase protection assays. The fmol^® DNA Cycle Sequencing System was used to directly sequence PCR products with [³³P]end-labeled primers. (1526)

Notes: The inhibitor was used to protect RNA during RT-PCR. (1671)

Notes: The TNT^® Coupled Transcription/Translation System was used to verify the 25.3kDa size of the cloned receptor. AMV reverse transcriptase was used for first strand cDNA synthesis prior to PCR. (1520)

Notes: Promega's Access RT-PCR system, Taq DNA Polymerase and PolyATtract^® mRNA Isolation System were used in this study. (1991)

Notes: The Altered Sites^® II in vitro Mutagenesis System was used to replicate mutations identified in patients with Glanzmann's Thrombasthenia. The cDNA was cloned into the pALTER^®-1 Vector and all mutation were confirmed by sequencing with the fmol^® DNA Cycle Sequencing System. (0660)